Converge Bio secured $5.5 million in seed funding, led by TLV Partners, to expand its platform that enhances the utility of biology-focused large language models (LLMs).
The startup addresses the complexities of adapting general-purpose LLMs for specialized biotech applications, such as antibody research, by offering tools for data enrichment, model fine-tuning, and explainability.
Their platform allows researchers to integrate proprietary data, predict outcomes like binding affinity, and identify key sequence components with precision. Its explainability feature has proven especially popular, enabling users to apply domain expertise to AI-generated insights, bridging bioinformatics and traditional lab workflows.
Converge Bio leverages open-source foundation models while developing proprietary processes, including its data enrichment and explainability methodologies, creating a strong competitive moat. The startup aims to become the go-to solution for generative AI in biotech, supporting applications such as antibody and vaccine design.
With the new funding, Converge Bio plans to expand its team, acquire more customers, and further its R&D efforts, including publishing a scientific paper on antibody design and training a dedicated foundation model.
